Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit ReviewAZD 4547 is a potent and selective FGFR1, FGFR3 and FGFR2 tyrosine kinase inhibitor (IC50 values are 0.2 1.8, and 2.5 nM, respectively). It shows selectivity for FGFR across a range of unrelated tyrosine and serine/threonine kinases, including IGFR (>2,900-fold), CDK2 (>50,000-fold), and p38 (>50,000-fold). In vitro, it has antiproliferative effects on tumor cell lines with deregulated FGFR expression. In vivo, AZD 4547 exhibits dose-dependent inhibition of tumor growth in an FGFR-driven human tumor xenograft mice model. It suppresses osteoclastogenesis and tumor-induced osteolysis in an orthotopic breast cancer bone metastasis mouse model. AZD 4547 is orally bioavailable.
分子量 | 463.56 |
公式 | C26H33N5O3 |
储存 | Store at -20°C |
纯度 | ≥98% (HPLC) |
CAS Number | 1035270-39-3 |
PubChem ID | 51039095 |
InChI Key | VRQMAABPASPXMW-HDICACEKSA-N |
Smiles | C[C@H]1CN(C2=CC=C(C=C2)C(NC3=NNC(CCC4=CC(OC)=CC(OC)=C4)=C3)=O)C[C@H](N1)C |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
溶剂 | 最高浓度 mg/mL | 最高浓度 mM | |
---|---|---|---|
溶解性 | |||
DMSO | 9.27 | 20 |
以下数据基于产品分子量 463.56。 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
浓度/溶剂体积/质量 | 1 mg | 5 mg | 10 mg |
---|---|---|---|
0.2 mM | 10.79 mL | 53.93 mL | 107.86 mL |
1 mM | 2.16 mL | 10.79 mL | 21.57 mL |
2 mM | 1.08 mL | 5.39 mL | 10.79 mL |
10 mM | 0.22 mL | 1.08 mL | 2.16 mL |
参考文献是支持产品生物活性的出版物。
Gavine et al (2012) AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family. Cancer Res. 72 2045 PMID: 22369928
Kang et al (2019) A selective FGFR inhibitor AZD4547 suppresses RANKL/M-CSF/OPG-dependent ostoclastogenesis and breast cancer growth in the metastatic bone microenvironment. Sci.Rep. 9 8726 PMID: 31217507
If you know of a relevant reference for AZD 4547, please let us know.
关键词: AZD 4547, AZD 4547 supplier, AZD4547, potent, selective, tyrosine, kinases, inhibitors, inhibits, FGFR, orally, bioavailable, osteolysis, cancer, osteoclastogenesis, 7823, Tocris Bioscience
引用文献是使用了 Tocris 产品的出版物。
目前没有 AZD 4547 的引用文献。 您是否知道使用了 Tocris AZD 4547 的优秀论文? 请告知我们.
目前没有该产品的评论。 Be the first to review AZD 4547 and earn rewards!
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意,Tocris 仅会向正规科研企业/机构地址发送文献。
Written by Kirsty E. Clarke, Victoria B. Christie, Andy Whiting and Stefan A. Przyborski, this review provides an overview of the use of small molecules in the control of stem cell growth and differentiation. Key signaling pathways are highlighted, and the regulation of ES cell self-renewal and somatic cell reprogramming is discussed. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.